All the news Showing 10 of 40 articles from: CirrhosisGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease Liz Highleyman / 24 April 2015 An oral regimen of sofosbuvir/ledipasvir (Harvoni) and ribavirin taken for 12 or 24 weeks produced sustained virological response rates of 85-88% for people with genotype 1 or 4 hepatitis C virus ... Merck HCV combination achieves 90% cure in advanced cirrhosis Keith Alcorn / 24 April 2015 A 12-week course of treatment with two direct-acting antivirals in development by Merck cured hepatitis C infection in 90% of people with very advanced cirrhosis and at imminent risk of liver failure, ... Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US Liz Highleyman / 05 March 2015 The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced fibrosis or cirrhosis and therefore being at ... Many hepatitis C patients with cirrhosis or advanced fibrosis face liver failure and liver cancer Liz Highleyman / 07 January 2015 Nearly one-third of chronic hepatitis C patients with liver cirrhosis and 12% with advanced fibrosis progressed to decompensation within five years, and 23% and 11%, respectively, died, according to a study presented ... Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection Liz Highleyman / 14 November 2014 An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates for treatment-naive and treatment-experienced people with genotype 1 hepatitis C ... Low uptake of HCV treatment in England will lead to substantial disease burden by 2035 Michael Carter / 24 June 2014 Only 3% of people with chronic hepatitis C virus (HCV) are treated for their infection each year in England, according to research published in the Journal of Hepatology. The current uptake of ... Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease Liz Highleyman / 17 April 2014 Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and people who experience severe hepatitis ... Successful hepatitis C treatment reduces risk of liver cancer and death, but most remain untreated Liz Highleyman / 19 November 2013 Hepatitis C treatment that leads to viral cure significantly reduces the likelihood of liver disease progression and liver-related mortality, but most people with hepatitis C remain untreated, according to a presentation at The Liver ... Britain faces a liver disease 'epidemic' The Guardian / 13 November 2013 BMS interferon-free combination cures over 90% of genotype 1 hepatitis C in 12 weeks Keith Alcorn / 06 November 2013 A combination of three direct-acting antivirals developed by Bristol-Myers Squibb cured chronic hepatitis C infection in over 90% of previously untreated patients in a mid-stage study, Gregory Everson of the University of Colorado ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive